Cargando…

Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists

Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors. Selective synthetic ligands for free fatty acid receptors (FFA1-4) have consequently b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watterson, Kenneth R., Hudson, Brian D., Ulven, Trond, Milligan, Graeme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/ https://www.ncbi.nlm.nih.gov/pubmed/25221541 http://dx.doi.org/10.3389/fendo.2014.00137

Ejemplares similares

The Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 (FFA4/GPR120)
por: Hudson, Brian D., et al.
Publicado: (2014)

Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands
por: Sergeev, Eugenia, et al.
Publicado: (2016)

Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets
por: Ulven, Trond
Publicado: (2012)

Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes
por: Christiansen, Elisabeth, et al.
Publicado: (2013)

Extracellular Ionic Locks Determine Variation in Constitutive Activity and Ligand Potency between Species Orthologs of the Free Fatty Acid Receptors FFA2 and FFA3
por: Hudson, Brian D., et al.
Publicado: (2012)

Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4
por: Watterson, Kenneth R., et al.
Publicado: (2017)

Defining the Molecular Basis for the First Potent and Selective Orthosteric Agonists of the FFA2 Free Fatty Acid Receptor
por: Hudson, Brian D., et al.
Publicado: (2013)

Concomitant Action of Structural Elements and Receptor Phosphorylation Determines Arrestin-3 Interaction with the Free Fatty Acid Receptor FFA4
por: Butcher, Adrian J., et al.
Publicado: (2014)

Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs
por: Hudson, Brian D., et al.
Publicado: (2012)

Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists: IDENTIFICATION OF THE STRUCTURAL AND CHEMICAL REQUIREMENTS FOR SELECTIVE ACTIVATION OF FFA2 VERSUS FFA3
por: Schmidt, Johannes, et al.
Publicado: (2011)

Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists
por: Valentini, Alice, et al.
Publicado: (2023)

Structure–Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators
por: Ulven, Elisabeth Rexen, et al.
Publicado: (2020)

A single extracellular amino acid in Free Fatty Acid Receptor 2 defines antagonist species selectivity and G protein selection bias
por: Sergeev, Eugenia, et al.
Publicado: (2017)

Chemogenetics defines a short-chain fatty acid receptor gut–brain axis
por: Barki, Natasja, et al.
Publicado: (2022)

Minireview: The Effects of Species Ortholog and SNP Variation on Receptors for Free Fatty Acids
por: Hudson, Brian D., et al.
Publicado: (2013)

Editorial: Obesity and Diabetes: Energy Regulation by Free Fatty Acid Receptors
por: Ichimura, Atsuhiko, et al.
Publicado: (2015)

Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2022)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

G protein‐coupled receptors not currently in the spotlight: free fatty acid receptor 2 and GPR35
por: Milligan, Graeme
Publicado: (2017)

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Oberle, Megan M., et al.
Publicado: (2019)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration
por: Jansen, Kirsten M., et al.
Publicado: (2023)

Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhu, Yuan, et al.
Publicado: (2021)

Three classes of ligands each bind to distinct sites on the orphan G protein-coupled receptor GPR84
por: Mahmud, Zobaer Al, et al.
Publicado: (2017)

Structural basis for the ligand recognition and signaling of free fatty acid receptors
por: Zhang, Xuan, et al.
Publicado: (2023)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Drug Discovery Opportunities and Challenges at G Protein Coupled Receptors for Long Chain Free Fatty Acids
por: Holliday, Nicholas D., et al.
Publicado: (2012)

Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis
por: Yuan, Xia, et al.
Publicado: (2023)

Free fatty acid receptors in the endocrine regulation of glucose metabolism: Insight from gastrointestinal-pancreatic-adipose interactions
por: Zhao, Yu-Feng
Publicado: (2022)

Free Fatty Acids and Their Metabolism Affect Function and Survival of Podocytes
por: Sieber, Jonas, et al.
Publicado: (2014)

Metabolic and inflammatory functions of short-chain fatty acid receptors
por: Bolognini, Daniele, et al.
Publicado: (2021)

Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes
por: Oh, Yoon S., et al.
Publicado: (2018)

Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study
por: Tsai, Chih-Yiu, et al.
Publicado: (2022)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Analysis of Intestinal Short-Chain Fatty Acid Metabolism Profile After Probiotics and GLP-1 Treatment for Type 2 Diabetes Mellitus
por: Min, Qiuxia, et al.
Publicado: (2022)

Long-chain saturated fatty acids and its interaction with insulin resistance and the risk of nonalcoholic fatty liver disease in type 2 diabetes in Chinese
por: Jiang, Li-Peng, et al.
Publicado: (2022)

Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis
por: Wei, Jinjing, et al.
Publicado: (2022)

Plasma Free Amino Acids and Risk of Cardiovascular Disease in Chinese Patients With Type 2 Diabetes
por: Li, Tie, et al.
Publicado: (2021)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2v1mc2lqor7u3rgrmsk0c69it3